Eastland Surgi Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.49 M
- Paid Up Capital ₹ 0.10 M
- Company Age 20 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.40 Cr
- Revenue Growth %
- Profit Growth 94.42%
- Ebitda 97.88%
- Net Worth -125.79%
- Total Assets -74.51%
About Eastland Surgi Pharma
Eastland Surgi Pharma Private Limited (ESPPL) is a Private Limited Indian Non-Government Company incorporated in India on 10 September 2004 and has a history of 20 years and four months. Its registered office is in Ludhiana, Punjab, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.49 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.40 Cr.
Ashwani Jain and Manish Jain serve as directors at the Company.
Company Details
-
Location
Ludhiana, Punjab, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24230PB2004PTC027473
-
Company No.
027473
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
10 Sep 2004
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Chandigarh
Industry
Who are the key members and board of directors at Eastland Surgi Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manish Jain
|
Director | 29-Apr-2023 | Current |
|
Ashwani Jain
|
Director | 15-Jul-2016 | Current |
Financial Performance of Eastland Surgi Pharma.
Eastland Surgi Pharma Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 94.42% increase in profit. The company's net worth observed a substantial decline by a decrease of 125.79%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Eastland Surgi Pharma?
In 2018, Eastland Surgi Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹24.00 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 2.40 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 27 Feb 2008 | Hdfc Bank Limited | ₹2.50 M | Open |
| 23 Feb 2008 | Hdfc Bank Limited | ₹2.15 Cr | Open |
How Many Employees Work at Eastland Surgi Pharma?
Unlock and access historical data on people associated with Eastland Surgi Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Eastland Surgi Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eastland Surgi Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
